Fig. 1
From: Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
The CD8HiIFNγHiCD33LowFOXP3Low immune profile is correlated with favorable clinical outcome. a,c Kaplan-Meier survival analysis of human sarcoma (a) and breast carcinoma (c) based on IFNγ gene copy number. The overall survival rates were stratified by IFNγ gene expression level: the 25% of patients with the highest IFNγ levels were placed in the IFNγHi group and the 25% with the lowest IFNγ levels were placed in the IFNγLow group. b,d Patients with sarcoma (b) and patients with breast cancer d were grouped by IFNγ, CD8, CD33, and FOXP3 gene expression levels: the 25% of patients in the IFNγHi group with the highest CD8a levels were placed in the CD8HiIFNγHi group, and the 25% of patients in the IFNγLow group with the lowest CD8a levels were placed in the CD8LowIFNγLow group. The CD8HiIFNγHi group and the CD8LowIFNγLow group were then substratified into the CD8HiIFNγHiCD33LowFOXP3Low group, the CD8HiIFNγHiCD33HiFOXP3Hi group, the CD8LowIFNγLowCD33LowFOXP3Low group, and the CD8LowIFNγLowCD33HiFOXP3Hi group. Kaplan-Meier analyses were used to determine the association of each group with a favorable survival outcome